Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
From Pharmaceutical Executive · · 2 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.